神经保护能否有效治疗原发性开角型青光眼？一项系统评价与荟萃分析方案。
Can neuroprotection effectively manage primary open-angle glaucoma? a protocol of systematic review and meta-analysis.
作者信息
Qi Yan-Xiu, Zhang Jian, Su Xing-Jie
机构信息
Department of Ophthalmology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
出版信息
Medicine (Baltimore). 2020 Jun 5;99(23):e20380. doi: 10.1097/MD.0000000000020380.
BACKGROUND
This study aims to assess the efficacy of neuroprotection (NP) for the management of patients with primary open-angle glaucoma (POAG).
METHODS
A comprehensive search will be carried out from the beginning to the February 29, 2020 in the electronic databases: Scopus, Web of Science, PUBMED, EMBASE, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, WANGFANG, and China National Knowledge Infrastructure. There are no limitations related to the language and publication date. Two researchers will independently undertake study selection from searched literatures, extract data from included trials, and appraise study quality using Cochrane risk of bias tool. Any disagreements will be solved by a third researcher through consultation. RevMan 5.3 software will be employed for statistical analysis.
RESULTS
This study will provide a high-quality synthesis of randomized controlled trials of NP for the management of patients with POAG.
CONCLUSIONS
The results of this study will help to create proposals for the treatment of POAG using NP.
SYSTEMATIC REVIEW REGISTRATION
INPLASY202040107.
背景
本研究旨在评估神经保护（NP）用于原发性开角型青光眼（POAG）患者治疗的疗效。
方法
将对电子数据库（Scopus、科学网、PubMed、EMBASE、Cochrane图书馆、护理及相关健康文献累积索引、万方和中国知网）从建库至2020年2月29日进行全面检索。无语言及发表日期限制。两名研究人员将独立从检索到的文献中进行研究筛选，从纳入的试验中提取数据，并使用Cochrane偏倚风险工具评估研究质量。任何分歧将由第三名研究人员通过协商解决。将采用RevMan 5.3软件进行统计分析。
结果
本研究将对NP治疗POAG患者的随机对照试验进行高质量的综合分析。
结论
本研究结果将有助于制定使用NP治疗POAG的方案。
系统评价注册
INPLASY202040107
Zotero 插件